Prostate cancer remains the second leading cause of cancer-associated deaths 
amongst American men. Trop2, a cell surface glycoprotein, correlates with poor 
clinical outcome and is highly expressed in metastatic, treatment-resistant 
prostate cancer. High levels of Trop2 are prognostic for biochemical recurrence. 
Trop2 regulates tumor growth and metastatic ability of prostate cancer. 
Moreover, overexpression of Trop2 drives the transdifferentiation to 
neuroendocrine phenotype in prostate cancer. In addition, Trop2 is overexpressed 
across epithelial cancers and has emerged as a promising therapeutic target in 
various solid epithelial cancers. The FDA (Food and Drug Administration) 
recently approved the use of a Trop2-targeting ADC (antibody-drug conjugate), 
Sacituzumab Govitecan (IMMU-132), for metastatic, triple-negative breast cancer 
with at least two prior therapies. Here, we review the role of Trop2 in prostate 
tumorigenesis and its potential as a promising biomarker and therapeutic target 
for prostate cancer.